The Filing Desk

Entera Bio

ENTX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ENTX · Last close · November 19, 2026
$3.28
Value Entera Bio yourself

Entera Bio's revenue fell 76.8% to $0 million in fiscal 2025. Its operating margin was −27,450.0%, down from −5,295.6% a year earlier. Free cash flow was −$7 million. The diluted share count rose 22.7%.

ENTERA BIO LTD. Latest fiscal year ended December 31, 2025 10-K filed March 27, 2026 · 0001178913-26-001797 Updated
Revenue
$0M
76.8%
Operating margin
−27,450.0%
22154.4 pts
Net income
−$11M
 
Free cash flow
−$7M
 
Return on equity
−108.0%
4.7 pts
Market cap
$476M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Diluted earnings per share for fiscal 2020 to 2025 is left blank: the SEC's structured data gives it the opposite sign from net income per share.

Charts show fiscal years, from the 10-K filings.

What Entera Bio does

Entera Bio is a drug developer based in Jerusalem, Israel, that is working to turn protein and peptide drugs, which today are almost always given by injection, into tablets that patients can swallow. Its technology, called N-Tab, is meant to protect these large molecules in the gut and help them pass into the bloodstream. It has no approved products and no sales yet.

Its most advanced drug candidate, EB613, is an oral version of teriparatide, a bone-building osteoporosis drug that Eli Lilly sells as the injection Forteo. Entera plans a final-stage (Phase 3) study of EB613 in postmenopausal women with osteoporosis, using the change in hip bone density as the main measure. Its other candidates include EB612, an oral treatment for hypoparathyroidism, a rare disorder that leaves too little calcium in the blood; an oral long-acting version of the same hormone; an oral GLP-1/glucagon tablet for obesity, developed with OPKO Health; and an oral GLP-2 tablet for short bowel syndrome. It says these would compete with injected drugs such as Ascendis Pharma's Yorvipath and Gattex.

Entera is small: at the end of 2025 it had 22 employees, all of its full-time staff in Israel. It has no sales force of its own and says it depends on deals with partners to develop and sell its products.

Its biggest risks, as it describes them

  • Its auditor has raised substantial doubt about its ability to keep going, and it needs more money to fund its studies.
  • Its drugs are all still in development and may fail in trials or never win approval.
  • Delays in starting or finishing the planned Phase 3 study of EB613.
  • Depending on partners to develop and sell its drugs, and on a few key staff.
  • Other companies' drugs, or another way to make peptide tablets, could prove better than its own.
From Entera Bio's annual report on Form 10-K, filed March 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Entera Bio lost money in fiscal 2025: a net loss of $11 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments25121197
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio8.0x9.6x10.3x7.6x6.9x
Quick ratio8.0x9.6x10.3x7.6x6.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Entera Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $140,880 of Entera Bio shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Mar 9, 2026Geno J GermanoDirectorBought20,000$1.30$26,000Form 4
Mar 5, 2026Sean EllisDirectorBought10,000$1.23$12,300Form 4
Feb 12, 2026Steven D RubinDirectorBought5,000$1.49$7,450Form 4
Feb 10, 2026Geno J GermanoDirectorBought20,000$1.49$29,800Form 4
Feb 10, 2026Haya TaitelDirectorBought7,500$1.48$11,100Form 4
Feb 9, 2026Sean EllisDirectorBought18,000$1.24$22,320Form 4
Feb 9, 2026Steven D RubinDirectorBought10,000$1.20$12,000Form 4
Dec 29, 2025Miranda Jayne ToledanoChief Executive Officer, DirectorBought11,000$1.81$19,910Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40——−17,879.2%
Altman Z''−20.43−34.49−20.27
Accruals ratio−12.7%−25.7%−32.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose——Fail
Revenue rose relative to assetsFailPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Entera Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Entera BioFY25−76.8%−27,450.0%−17,802.4%———
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——00010000
Revenue growth———−52.8%54.7%56.4%−76.5%−100.0%—−76.8%
Gross profit———0000000
Research and development3387676446
Operating income−5−11−11−12−11−12−13−9−10−12
Net income−1−11−10−11−11−12−13−9−10−11
Diluted EPS (US$)0.782.491.310.89——————
Diluted shares (millions)74812192629293846
Cash flow
Cash from operations−3−4−10−9−11−9−12−7−7−7
Capital expenditure0000000000
Free cash flow−3−5−10−9−11−9−13−7−7−7
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation2512122233
Balance sheet at fiscal year end
Cash and short-term investments412815925121197
Debt incl. finance leases—4————————
Total assets—13131710261312916
Total liabilities—4535231113
Shareholders' equity−25−3210148231210813
Margins and ratios
Gross margin———11.0%17.8%34.7%24.6%—5.0%0.0%
Operating margin——−2,172.2%−4,853.4%−3,059.7%−2,139.6%−9,714.2%—−5,295.6%−27,450.0%
Net margin——−2,060.8%−4,574.1%−3,072.9%−2,134.3%−9,754.5%—−5,271.3%−27,235.7%
Free cash flow margin——−1,972.8%−3,796.2%−2,906.8%−1,590.2%−9,362.7%—−3,768.5%−17,802.4%
Rule of 40 (growth + FCF margin)———−3,849.0%−2,852.2%−1,533.8%−9,439.2%——−17,879.2%
Return on capital——————————
Return on equity———−90.4%−105.4%−81.0%−76.2%−80.3%−103.3%−108.0%
Return on assets——−77.4%−71.9%−84.9%−68.3%−66.8%−71.4%−90.2%−90.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Entera Bio's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Entera Bio.